Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase
about
Drug-induced reactivation of apoptosis abrogates HIV-1 infectionRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesMetal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsMitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?Melanocytes as instigators and victims of oxidative stressPhase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Thioredoxin Reductase from Thermoplasma acidophilum : A New Twist on Redox Regulation † , ‡TrxR1 as a potent regulator of the Nrf2-Keap1 response systemMotexafin gadolinium in the treatment of brain metastasesThioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signalingTargeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assayThe selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities.Comparison of proton and electron radiation effects on biological responses in liver, spleen and blood.Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potentialRedox control systems in the nucleus: mechanisms and functions.Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignanciesMonte Carlo study of radiation dose enhancement by gadolinium in megavoltage and high dose rate radiotherapy.Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenesIncreased reactive oxygen species production during reductive stress: The roles of mitochondrial glutathione and thioredoxin reductases.Impact of trivalent arsenicals on selenoprotein synthesisRibonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.Motexafin gadolinium: a novel radiosensitizer for brain tumors.EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells.Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.Targeting selenium metabolism and selenoproteins: novel avenues for drug discoveryTexaphyrins: tumor localizing redox active expanded porphyrinsMotexafin gadolinium: a promising radiation sensitizer in brain metastasis.Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis.Thioredoxin reductase and its inhibitors.Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells.
P2860
Q21090718-6FEC7ECB-2C55-49A8-8D9C-E28B9670DE67Q24645584-7885EA59-9F52-4EE9-8EA8-35CCFEA24E52Q26800031-B25B8B61-DF30-40D8-9256-FEBC55728B89Q26852282-9AF8D9D0-BA93-4CF4-9B22-D0A7182B5F4EQ26998576-EEA00580-5CBA-48C9-BBD8-271B52EE4C88Q27310843-729CE2E0-6FB2-4D16-963A-1AC64C4D4C01Q27651732-0BC3D2DC-F791-4807-AD70-5C0541B2EC64Q28080723-F9A7C340-9338-4FC9-BCB4-DCD0E5FD7301Q28285963-4DA84D67-9B33-472A-8470-840CD6AB88ECQ28389739-5297E9C2-BB5B-4AEF-BF4F-83A844CDE1FAQ33291299-22915098-0B21-41F6-AB71-A77E6F56D3F5Q33526346-224F9F72-0E40-4E8D-9427-E3B74A89AAF7Q33741157-93FE58A2-257B-472F-A5C1-90DA87E2AB0AQ33801828-1C0BF860-1A8A-4D47-A7A1-7309AC122378Q33967269-2A31327B-52BD-418D-9544-7C14F42B6A8AQ34061008-08678785-CA65-4EDF-AE4E-6F49C8AFC006Q34110107-3A1837F4-C60B-42D4-9DD6-70278864ABBDQ34110120-7D133543-8C23-43B8-9F85-ECCAB82CACA2Q34570658-D66BDB1A-0BE9-46A4-B7B5-CE96B6E12345Q35294967-FA9BA7CA-38C3-4277-A405-9A27B76C1B3CQ35535940-70A534F6-1D60-4500-9ED5-271F7EE2878CQ35588949-742420FF-7EA8-45F1-9687-98C783EA8620Q35745069-B8A5B521-46B6-4FB5-AE0D-107427FB6E9FQ35971759-72FA668F-C59B-477C-A2B9-9AA51D711CABQ36408318-5F8DDF3B-392F-483F-96DA-17DE5D75E4BBQ36485991-C652A309-5C4B-4A15-8331-0ABDC8D7FC14Q36753557-52153448-FFD4-4D1D-A159-7A26E6A08FE0Q36842747-8D42AE07-F837-4004-9E5F-ED69B3AE162BQ36916338-49D77171-8EDA-4FDB-8B04-D28596ADA740Q37152041-223C937A-B138-4845-85BA-4D907FDBB9D2Q37205903-75AD48A9-4CF2-4313-A35E-67AA2D315F09Q37390535-916BAAC1-383C-457D-996E-BEAEBC3E09D6Q37642550-BBD3C6CE-AAFA-4104-BD6F-E7E45A137675Q37808628-B64C408D-2343-4E43-81B6-5C8A4D7A3E34Q37847606-FE983099-881C-4E76-B2C1-F42AA516AFEAQ38014582-27E0DCE1-61EF-4D7D-9BA8-BBA509D1DB0CQ38090392-DADE3D4B-0346-4057-AA06-29348EF8F18AQ38215943-AB1E5B18-9F65-4C01-9A08-E50CFF4FE80DQ38669290-F3DC1B1C-4897-4BC7-AB9B-9AF1EFA764D7Q39822905-9D8FFE34-B1BE-49C6-BD28-9F7BE988D774
P2860
Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase
description
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2006
@ast
im April 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/04/21)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/04/21)
@nl
наукова стаття, опублікована у квітні 2006
@uk
name
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@ast
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@en
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@nl
type
label
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@ast
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@en
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@nl
prefLabel
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@ast
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@en
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@nl
P2860
P356
P1476
Motexafin gadolinium, a tumor- ...... e and ribonucleotide reductase
@en
P2093
Arne Holmgren
Johanna S Ungerstedt
P2860
P304
10691-10697
P356
10.1074/JBC.M511373200
P407
P577
2006-02-14T00:00:00Z